HK Stock Market Move | UNITED LAB (03933) rose more than 6%, with a 27% year-on-year increase in net profit attributable to shareholders in the first half of the year. Several products in the formulation product segment have achieved key progress.

UNITED LAB (03933) rose more than 6%, as of the time of publication, it is up 4.56%, trading at HK$17.19, with a turnover of HK$1.8 billion. On the news front, recently, UNITED LAB announced its performance for the first half of 2025. CICC pointed out that in the first half of 2025, the company's operating income was HK$7.519 billion, a year-on-year increase of +4.8%; gross profit was HK$3.924 billion, with a gross profit margin of 52.2%, up by +5.6 percentage points year-on-year; pre-tax profit was HK$2.420 billion, up by +27.24% year-on-year; and achieved a net profit of HK$1.894 billion, up by +27.02% year-on-year. The growth was mainly benefited from the one-time contribution of the licensing fee for Novo Nordisk's UBT251 and the significant increase in sales of insulin series, in line with the bank's expectations. Guotai Junan Securities released a research report stating that the company's research projects are progressing smoothly, and several products in the formulation product segment have made key progress, including the approval and launch of Liraglutide injection, the approval of Polyvinyl Alcohol eye drops, the acceptance of the marketing application for Semaglutide injection, and the approval of Ceftriaxone Sodium Injection through generic consistency evaluation. The company has also reached a licensing agreement with Novo Nordisk for UBT251, further improving its layout in innovative drug cooperation.